Alirocumab, page-22

The last 3 minutes of the Piper Jaffery audio tape.
, AS answers some financial questions
Presently, just over $10 mil in cash, burn rate about $4 mil per month and this low cash balance is on purpose because Sanofi has paid $50 mil exclusivity fees and Hikma to pay $40 mil exclusivity fees. I am sure that he said somewhere due this quarter.
i am not sure if Sanofi $50 mil is an additional exclusivity fee for the Wearable Injectors on top of the first $50 mil for the development of the Unifill glass retractable safety syringe.
the slide show that accompanies the audio has a good chart that shows the CAGR (compound annual growth rate) predicted for each product.
The wearable injectors has a CAGR of 108%, which means that production will double each year and that is a high profit product, North of between $10 and $15 per unit.
i have no doubt about the hockey stick income growth and it will be preceeded by the same SP rise.
The real secret to this stock is the low number of shares, about 110 mil, which means that profitability when it comes and that will be soon because Flextronics and PHARMAS are going to bear most of the production costs and set up cost burden and so for a measly $110 mil excess profit relates to $1 per share.
most US companies only pay about 1 to 2 % dividend and Apple and other cash rich companies, do no know how to reward their shareholders.
I feel confident that AS does.